Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes
Toxicological Sciences · 2024
DOI: 10.1093/toxsci/kfae044 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Toxicological Sciences, 2024. Verfasst von Melissa M Heintz und 6 weiteren Autor:innen. Beteiligte Einrichtung: ToxStrategies LLC, Asheville, North Carolina 28801, USA. Hauptthemen laut MEDLINE: Hepatocytes, PPAR alpha, PPAR gamma, Transcriptome. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Chemours Company FC.
Abstract (Originalsprache)
Like many per- or polyfluorinated alkyl substances (PFAS), toxicity studies with HFPO-DA (ammonium, 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate), a short-chain PFAS used in the manufacture of some types of fluorinated polymers, indicate that the liver is the primary target of toxicity in rodents following oral exposure. Although the current weight of evidence supports the PPARα mode of action (MOA) for liver effects in HFPO-DA-exposed mice, alternate MOAs have also been hypothesized including PPARγ or cytotoxicity. To further evaluate the MOA for HFPO-DA in rodent liver, transcriptomic analyses were conducted on samples from primary mouse, rat, and pooled human hepatocytes treated for 12, 24, or 72 h with various concentrations of HFPO-DA, or agonists of PPARα (GW7647), PPARγ (rosiglitazone), or cytotoxic agents (ie, acetaminophen or d-galactosamine). Concordance analyses of enriched pathways across chemicals within each species demonstrated the greatest concordance between HFPO-DA and PPARα agonist GW7647-treated hepatocytes compared with the other chemicals evaluated. These findings were supported by benchmark concentration modeling and predicted upstream regulator results. In addition, transcriptomic analyses across species demonstrated a greater transcriptomic response in rodent hepatocytes treated with HFPO-DA or agonists of PPARα or PPARγ, indicating rodent hepatocytes are more sensitive to HFPO-DA or PPARα/γ agonist treatment. These results are consistent with previously published transcriptomic analyses and further support that liver effects in HFPO-DA-exposed rodents are mediated through rodent-specific PPARα signaling mechanisms as part of the MOA for PPARα activator-induced rodent hepatocarcinogenesis. Thus, effects observed in mouse liver are not appropriate endpoints for toxicity value development for HFPO-DA in human health risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ToxStrategies LLC, Asheville, North Carolina 28801, USA.
- ToxStrategies LLC, Austin, Texas 78731, USA.
- BioIVT LLC, Kansas City, Kansas 66103, USA.
- ToxStrategies LLC, Katy, Texas 77494, USA.
ORCID-Profile: Melissa M Heintz, William D Klaren
Förderung
- The Chemours Company FC
Zitieren
APA
Heintz, M. M., Klaren, W. D., East, A. W., Haws, L. C., McGreal, S. R., Campbell, R. R., & Thompson, C. M. (2024). Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae044
Vancouver
Heintz MM, Klaren WD, East AW, Haws LC, McGreal SR, Campbell RR, et al. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes. Toxicological Sciences. 2024. doi:10.1093/toxsci/kfae044
BibTeX
@article{Heintz2024,
author = {Heintz, Melissa M and Klaren, William D and East, Alexander W and Haws, Laurie C and McGreal, Steven R and Campbell, Rebecca R and Thompson, Chad M},
title = {Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes},
journal = {Toxicological Sciences},
year = {2024},
doi = {10.1093/toxsci/kfae044}
}
EUVIMED